Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.

Ramy Abdelmaseih; Randa Abdelmasih; Mustajab Hasan; Alan Hamza

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.

Ramy Abdelmaseih
, Randa Abdelmasih
, Mustajab Hasan
, Alan Hamza

HCA Florida Ocala Hospital

HCA Healthcare

Research output: Contribution to journal › Article › peer-review

Abstract

Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.

Original language	American English
Journal	Internal Medicine
State	Published - Jun 1 2021

Keywords

arrhythmia
atrial fibrillation
ekg
evolocumab
hyperlipidemia
pcsk-9 inhibitor

Disciplines

Cardiovascular Diseases
Internal Medicine

Access to Document

https://doi.org/10.7759/cureus.15467

Cite this

@article{c3b50023659445809f3b409ae097eede,

title = "Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.",

abstract = " Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.",

keywords = "arrhythmia, atrial fibrillation, ekg, evolocumab, hyperlipidemia, pcsk-9 inhibitor",

author = "Ramy Abdelmaseih and Randa Abdelmasih and Mustajab Hasan and Alan Hamza",

note = "Abdelmaseih R, Abdelmasih R, Hasan M, Hamza A. Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab. Cureus. 2021;13(6):e15467. doi:10.7759/cureus.15467",

year = "2021",

month = jun,

day = "1",

language = "American English",

journal = "Internal Medicine",

}

TY - JOUR

T1 - Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.

AU - Abdelmaseih, Ramy

AU - Abdelmasih, Randa

AU - Hasan, Mustajab

AU - Hamza, Alan

N1 - Abdelmaseih R, Abdelmasih R, Hasan M, Hamza A. Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab. Cureus. 2021;13(6):e15467. doi:10.7759/cureus.15467

PY - 2021/6/1

Y1 - 2021/6/1

N2 - Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.

AB - Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.

KW - arrhythmia

KW - atrial fibrillation

KW - ekg

KW - evolocumab

KW - hyperlipidemia

KW - pcsk-9 inhibitor

UR - https://scholarlycommons.hcahealthcare.com/internal-medicine/192

UR - https://doi.org/10.7759/cureus.15467

M3 - Article

JO - Internal Medicine

JF - Internal Medicine

ER -

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.

Abstract

Keywords

Disciplines

Access to Document

Other files and links

Cite this